Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies [PDF]
DiPersio, John F, et al,
core +1 more source
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases [PDF]
Ruben A. Mesa +5 more
openalex +1 more source
Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis. [PDF]
Coltro G +6 more
europepmc +1 more source
Accelerating myelofibrosis through loss of Dnmt3a [PDF]
Radek C. Skoda
openalex +1 more source
The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies. [PDF]
Reynolds SB, Komrokji R, Kuykendall AT.
europepmc +1 more source
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]
Abboud, Camille N.
core +1 more source
Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET [PDF]
Laëtitia Vercellino +11 more
openalex +1 more source
Nutritional factors and survival in a cohort of patients with myelofibrosis. [PDF]
Buscemi S +11 more
europepmc +1 more source
Masking as Myelofibrosis: A Case of Tp53 Mutated Acute Erythroid Leukemia Presenting With Pancytopenia and Bone Pain. [PDF]
Parker K, Cutrer RC.
europepmc +1 more source

